Literature DB >> 17827748

Effects of oseltamivir phosphate (Tamiflu) and its metabolite (GS4071) on monoamine neurotransmission in the rat brain.

Kanako Satoh1, Ryouichi Nonaka, Akio Ogata, Dai Nakae, Shin-Ichi Uehara.   

Abstract

As abnormal behaviors such as jumping and falling from balcony were reported in patients aged 10 to 19 years who administrated oseltamivir phosphate (Tamiflu) for treatment influenza infection, the Ministry of Health, Labor and Welfare in Japan notified that, as a rule, Tamiflu should not be prescribed to patients aged 10 to 19 years. To examine the relationship between Tamiflu and abnormal behaviors, we investigated the effects of Tamiflu and its carboxylic acid metabolite, GS4071, on the central nervous system, that is, on 3 neurotransmitters (dopamine, serotonin, and norepinephrine) in presynapses (inhibition of re-uptake, promotion of release) and postsynapses (guanosine 5'-triphosphate (GTP) gammaS binding), using rat brain synaptosomes. Neither Tamiflu nor GS4071 influenced the re-uptake/release of the 3 monoamines or GTP binding in postsynapses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827748     DOI: 10.1248/bpb.30.1816

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  4 in total

1.  In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite.

Authors:  Lothar Lindemann; Helmut Jacobsen; Diana Schuhbauer; Frederic Knoflach; Silvia Gatti; Joseph G Wettstein; Hansruedi Loetscher; Tom Chu; Martin Ebeling; James C Paulson; Eric Prinssen; Manfred Brockhaus
Journal:  Eur J Pharmacol       Date:  2009-11-14       Impact factor: 4.432

2.  Oseltamivir prescription and regulatory actions vis-à-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database.

Authors:  Hisashi Urushihara; Yuko Doi; Masaru Arai; Toshiyuki Matsunaga; Yosuke Fujii; Naoko Iino; Takashi Kawamura; Koji Kawakami
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

3.  Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir.

Authors:  Miki Hiasa; Yumiko Isoda; Yasushi Kishimoto; Kenta Saitoh; Yasuaki Kimura; Motomu Kanai; Masakatsu Shibasaki; Dai Hatakeyama; Yutaka Kirino; Takashi Kuzuhara
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

4.  Psychiatric Symptoms in a Patient with Influenza A (H1N1) Treated with Oseltamivir (Tamiflu): A Case Report.

Authors:  Sang Won Jeon; Changsu Han
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-08-31       Impact factor: 2.582

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.